

Lecture Note

**Subject: HAP, 404T,
SEM-4th UNIT-IV**

**Submitted By: Arun Panda Sir
Hi-Tech College of Pharmacy**

DRUGS USED IN EPILEPSY

Epilepsy is a common neurological problem affecting about 0.5% of the population, the aetiology being unknown in most of the patients. An epileptic seizure or 'fit' is caused by an episodic brief unphysiological synchronous high frequency discharge of impulses by a group of neurones in the brain. The abnormal local discharge may then spread to other areas of the brain. The locus of the primary abnormal neuronal discharge and the extent of its spread determines the nature of the symptoms. The abnormal electrical activity during a seizure can be recorded by an electroencephalograph (EEG), and the different types of seizures can be recognized on the basis of the locus, nature and spread of the abnormal discharge.

Epilepsy can be *categorized* into

(a) **Partial (focal) seizures.** The symptoms of these seizures depend upon the site of excessive neuronal discharge and the extent to which the abnormal electrical activity spreads to other brain neurones. Though initially localized, the seizures may later progress and intensify to become generalized tonic-clonic seizures.

(i) *Simple partial seizures.* Abnormal electrical activity is confined to a localized area of motor cortex so that the seizures are limited to one limb or a group of muscles controlled by that particular brain region. There is some sensory disturbance but no loss of consciousness. Also known as **Jacksonian epilepsy**. These seizures can occur at any age.

(ii) *Complex partial seizures* (psychomotor or temporal lobe epilepsy). There is complex sensory hallucinations, bizarre behaviour and loss of consciousness. Motor movements may be repetitive in nature (stereotypy). Incidence is usually below the age of 20 years.

(b) **Generalized seizures.** These seizures involve abnormal electrical discharge throughout both hemispheres. Though the seizures may be

convulsive or nonconvulsive, there is usually an immediate loss of consciousness.

(i) **Tonic-clonic (grand mal) seizures.** Commonest type of epilepsy. There is loss of consciousness followed by tonic, and then clonic, phases. The seizure is followed by a postictal period of confusion, muscle weakness and exhaustion.

(ii) **Absence (petit mal) seizures.** There is a brief, abrupt and self-limiting loss of consciousness, but no convulsions. The patient is usually prepubertal and exhibits vacant stare with rapid eye-blinking lasting for a few seconds.

(iii) **Myoclonic seizures.** These seizures consist of short episodic convulsions, which may reoccur after a few minutes. They may occur at any age and are usually due to underlying permanent neurologic damage.

(iv) **Febrile seizures.** Young children may exhibit convulsions concomitant with hyperpyrexia. They are of tonic-clonic type and are of short duration. They do not cause any neurologic damage and rarely require medication.

(v) **Status epilepticus.** These are rapid recurrent grand mal seizures. This is an emergency condition requiring immediate treatment.

1. Classification of antiepileptic drugs

Antiepileptic agents are conveniently classified according to their clinical use:

A. Drugs used in partial seizures

Phenytoin, and congeners, mephenytoin, ethotoin and phenacemide, **carbamazepine** and oxcarbazine, **phenobarbitone**, **primidone**, vigabatrin, lamotrigine, felbamate, gabapentin, topiramate, tiagabine, zonisamide, levetiracetam.

B. Drugs used in generalized seizures

(a) For tonic-clonic (grand mal) seizures: same drugs as used for partial seizures, **sodium valproate**

(b) For absence (petit mal) seizures: **ethosuximide** and congeners phensuximide and thsuximide, **sodium valproate**, **trimethadione** congeners paramethadione and dimethadione,

clonazepam, **clobazam**, **lamotrigine**, **zonisamide** (as adjunct), **topiramate**

(c) For myoclonic seizures: **Sodium valproate**

clonazepam, felbamate

(d) For infantile seizures

Phenobarbitone, primidone, clonazepam, ethosuximide had been used in non-febrile infantile seizures.

C. Drugs used in status epilepticus

Diazepam (i.v.), lorazepam (i.v.), phenobarbitone (i.v.), phenytoin (i.v.)

2. Mechanism of action

The mechanisms involved in antiepileptic action are poorly understood. Basically, the mechanisms are likely to be involved, stabilization of the membrane potential, increase in seizure threshold, and inhibition of the spread of the seizure activity by blocking synaptic transmission at some point. Thus, drugs which reduce Na^+ conductance and reduce Ca^{2+} influx will attenuate action potential generation in excitable cells and increase seizure threshold. The inhibition of the spread of the seizure activity may be mediated through an increase in the activity of the inhibitory neurotransmitters like **GABA**, and possibly glycine. Recent evidence suggests that inhibition of excitatory neurotransmitter (mainly **glutamate**) activity may also be responsible for attenuation of spread of seizure activity. The role of catecholamines (noradrenaline and dopamine) and 5-HT are unclear. However, phenytoin and some other antiepileptics are known to inhibit release of noradrenaline and 5-HT and promote the uptake of dopamine. The likely mechanisms involved in antiepileptic drug action are given in Table 8.12.

3. Pharmacokinetics

The pharmacokinetic data of commonly used antiepileptics are summarized in Table 8.10.

4. Therapeutic uses

The drugs of choice and their alternatives for the treatment of different types of epilepsy are given in Table 8.11. The following guidelines are adopted to initiate and maintain therapy:

(a) Treatment should be initiated with

Pharmacokinetic data

Phenobarbitone	Well absorbed from gut. 75% metabolized in liver rest excreted unchanged alkaline urine
Phenitoin	Well absorbed from gut. Metabolized in liver by CYP2C9. Rate of inactivation follows Michaelis-Menten kinetics. Genetic variations in rate
Carbamazepine	Well absorbed from gut. Initial half-life reduced on enzyme induction. Metabolites are also active
Valproic acid	Well absorbed from gut. Excreted as conjugate in urine. 90% protein bound.
Ethosuximide	Well absorbed from gut. Excreted in urine as unchanged drug.
Clonazepam	Gut absorption slow, erratic. High protein binding.
Clobazam	Gut absorption slow, erratic. High protein binding. Renal excretion of unchanged drug.

drug, with careful monitoring of dosage. In saliva or plasma drug concentrations should be assessed to ensure adequate therapeutic concentrations of the drug.

Partial simple	Phenytoin, carbamazepine
Partial complex	Phenytoin, carbamazepine
Grand mal	Phenytoin, carbamazepine
Petit mal	Ethosuximide, sodium valproate
Myoclonic	Sodium valproate, clonazepam, clobazam
Infantile febrile seizures	Phenobarbitone, clonazepam
Status epilepticus	Diazepam, lorazepam, phenytoin

Phenobarbitone, primidone, gabapentin, vigabatrin, lamotrigine
Primidone
Phenobarbitone, primidone, vigabatrin, lamotrigine, gabapentin
Clonazepam, clobazam, lamotrigine
Phenytoin, zonisamide
Primidone
Phenobarbitone

5. Adverse reactions

All antiepileptic agents produce unwanted effects, particularly because of long term use. Individual adverse effects are given in Table. 8.12.

Pregnancy, lactation and antiepileptic drugs:

All the antiepileptic agents used cross the placental barrier and are excreted in mother's milk. Antiepileptics, particularly phenobarbitone and phenytoin, have been implicated in causation of cleft palate, hare lip and cardiac malformations. Folate deficiency induced by phenobarbitone, and phenytoin, have been implicated in causation of cleft palate, hare lip and cardiac malformations. Folate deficiency induced by phenobarbitone, phenytoin, sodium valproate, and to a lesser extent carbamazepine, is held responsible for spina bifida. As such, folate supplements are essential. Carbamazepine appears to be the safest drug in epileptics in the child bearing age (see Chapter 16).

Phenobarbitone induces sedation, hypotonis and suckling defects in breastfed infants, a feature also noted with clonazepam. New born babies and breastfed infants of mothers on antiepileptic therapy, sometimes show reduction in vitamin K-sensitive clotting factors.

Drug interactions

Most of the clinically relevant adverse drug-drug interactions between antiepileptics and other drugs are due to their pharmacokinetic properties. Thus, they may induce displacement of other drugs

from plasma protein binding sites, or induce microsomal enzymes and increase the metabolism of other drugs, and often their own metabolism well. Important drug interactions are given in Table 8.13.

7. Newer antiepileptic agents

(a) **Vigabatrin.** This drug (gamma-aminobutyrate aminotransferase (GABA-T), the major enzyme responsible for GABA inactivation. Vigabatrin increases GABA levels at synaptic sites, and also potentiates GABA action by inhibiting the GABA transporter. It is well absorbed following oral administration and half-life is 6-8 hours. It is minimally plasma protein bound and is excreted in the kidneys. It is useful in treatment of partial seizures. Dosage is 500 mg twice daily, to a total daily dose of 2-3 g. Toxicity includes drowsiness, dizziness and weight gain, agitation, mental confusion and psychosis. Existing mental disease is a major contraindication. Long term use has been associated with visual defects.

(b) **Lamotrigine.** Its actions resemble phenytoin and the drug has some antifolate activity. It is well absorbed on oral administration, is moderately protein bound and is excreted as a glucuronide conjugate by kidney. Half-life is 25-35 hours and daily doses range between 100-200 mg

...availability. a half-life of 5-8 h
faeces and through u
as an adjunct drug
ranging from 16 mg
Adverse effects inc
tremors, ataxia, met
rarely, psychosis and

(c) **Gabapentin**. This drug, a *GABA analogue* does not act directly on *GABA receptors* but increases synaptic *GABA* activity by increasing its release and by inhibiting *GABA uptake*. It is fairly well absorbed after oral administration, is not metabolized and excreted unchanged in urine. Half-life ranges between 5 to 8 hours and has, therefore, to be administered 2-3 times a day, total dose being 2400 mg/day. It is effective against *partial and grand mal seizures*, and effective in *neuropathic pain*. Adverse effects include drowsiness, dizziness, tremors and ataxia.

(d) **Felbamate**. Its mechanism of action is unclear but is believed to block *NMDA receptors* via *glycine binding site*. It is absorbed orally and has a half-life of 20 hours. It is excreted mainly in unchanged form, and to some extent as conjugates, in urine. It increases plasma levels of phenytoin and sodium valproate, but decreases that of carbamazepine. Felbamate is effective mainly in *partial seizures*. Adverse effects like aplastic anaemia and hepatitis limit its use.

(e) **Topiramate**. It differs from other antiepileptic agents being a substituted succinimide. It appears to have multiple mechanisms of action including blockade of voltage-gated sodium channels, potentiation of *GABA* activity and inhibition of kainate effect on *AMPA receptors*. The drug is rapidly absorbed, minimally protein bound and moderately metabolized. Primary excretion is renal and half-life is 20-30 hours. It is effective against *partial and grand mal seizures*, but does not have an effect on absence seizures. The dose ranges from 200 to 600 mg/day. Adverse effects include drowsiness, dizziness, mental depression, anxiety, paraesthesia, cognitive slowing

...availability. a half-life of 5-8 h
faeces and through u
as an adjunct drug
ranging from 16 mg
Adverse effects inc
tremors, ataxia, met
rarely, psychosis and

(g) **Zonisamide** which appears to act as a *calcium channel blocker* and *calcium channel blocker* in *infantile seizures*. It is poorly absorbed, minimally metabolized and excreted, with a half-life from 100 to 600 minutes. Adverse effects include drowsiness, ataxia.

(h) **Levetiracetam** (agent) analogue of *gabapentin*. Its mechanism of action is unclear. On oral administration, it is excreted in urine. Its half-life is 6-8 hours. The dose is 1000 mg twice daily. Adverse effects include drowsiness, ataxia and *partial seizures*.

8. Treatment of status epilepticus

Status epilepticus is a medical emergency. The drugs used for its treatment are instit... (2 mg/min, maximum dose 30 mg/min, maximum duration 30 minutes). Diazepam has rapid onset but sustained effects do not persist, the i.v. dose is 0.1 to 0.2 mg/kg to 100 mg/min. These drugs induce hypotension, ad

7. Newer antiepileptic agents

(a) **Vigabatrin.** This drug (gamma-aminobutyric acid transaminase inhibitor) is an *irreversible inhibitor* of *gamma-aminotransferase (GABA-T)*, the major enzyme responsible for GABA inactivation. Apart from increasing GABA levels at synaptic sites, Vigabatrin also potentiates GABA action by inhibiting GABA transporter. It is well absorbed following oral administration and half-life is 6-8 hours. It is minimally plasma protein bound and is excreted in kidneys. It is *useful in treatment of partial seizures* and to some extent in grand mal and infantile seizures. Dosage is 500 mg twice daily, increasing to a total daily dose of 2-3 g. Toxicity includes drowsiness, dizziness and weight gain, and rarely agitation, mental confusion and psychosis. Pre-existing mental disease is a major *contraindication*. Long term use has been associated with visual effects.

(b) **Lamotrigine.** Its actions resembles that of phenytoin and the drug has some antifolate action also. It is well absorbed on oral administration. Moderately protein bound and excreted as glucuronide conjugate by kidney. Half-life is 24 hours and daily doses range between 100 to 300 mg.

is well absorbed after oral administration with nearly 100% bioavailability. It is highly protein bound with a half-life of 5-8 hours. Excretion is mainly via faeces and through urine. Tiagabine has been used as an adjunct drug for partial seizures in doses ranging from 16 mg to 56 mg/day in divided doses. Adverse effects include drowsiness, dizziness, tremors, ataxia, mental confusion, depression, and rarely, psychosis and skin rashes.

(g) **Zonisamide.** It is a sulphonamide derivative which appears to act mainly on voltage gate sodium and calcium channels. The drug is effective against partial and grand mal seizures, and also finds use in infantile seizures and myoclonus. It is well absorbed, minimally protein bound and renally excreted, with a half-life of 1-3 days. Doses range from 100 to 600 mg/day. Adverse effects include drowsiness, ataxia and cognitive impairment.

(h) **Levetiracetam.** It is a piracetam (nootropic agent) analogue whose mode of action remains unclear. Complete absorption after oral administration, minimal protein binding and excretion via urine mainly in unchanged form. Half-life is 6-8 hours and dosage ranges from 500 to 1000 mg twice daily. Adverse effects include drowsiness, ataxia, and asthenia. It is used mainly in partial seizures.

8. Treatment of status epilepticus

Status epilepticus is an emergency condition. The drugs used are given in Table 8.11. Drug treatment is instituted with i.v. diazepam infusion (2 mg/min, maximum dose given is 20 mg in adults) given concurrently with phenytoin i.v. infusion (50 mg/min, maximum dose 1000 mg in adults). Diazepam has rapid onset and short duration of anticonvulsant effect, while phenytoin has slow onset but sustained duration of action. If seizures persist, the i.v. dose of phenytoin can be increased to 100 mg/min, maximum dose 1500 mg. Since these drugs induce respiratory depression and hypotension, adequate measures have to be taken for cardio-respiratory support, EEG monitoring

Well absorbed from gut. Excreted as glucuronide conjugate in urine. 90% plasma protein bound.

Well absorbed from gut. Extensively plasma protein bound. Excreted in urine as conjugates.

Gut absorption slow, erratic. Moderate binding to plasma protein. Renal excretion of conjugated metabolites. Clon Clo

drug, with careful monitoring of dosage. If possible, saliva or plasma drug concentrations should be assessed to ensure adequate therapeutic concentrations of the drug, and the dose is adjusted accordingly. Or else, the maximum tolerated dose of drug should be established.

(b) A **second drug is added** to the regimen if seizures are not controlled despite maintaining adequate therapeutic serum concentrations of first drug or if the first drug induces unacceptable adverse effects in the given dose. Addition of the second drug may make it possible to reduce the dose, and hence minimize adverse effects of the first drug.

Abrupt withdrawal of a given drug can precipitate seizures and even status epilepticus. **Withdrawal has to be gradual.**

If seizures are not controlled by a given drug even after 3-4 months of use, the drug combination is withdrawn and substituted by another drug from a different chemical group.

Alternative drug
controlled.

(e) Drugs are given in **daily doses**. Sustained doses given once daily.

(f) **Dose increase** is gradually at intervals until maximal tolerated plasma levels in the absence of adverse concentrations have been reached.

(g) **Plasma drug monitoring** is desirable in patients with renal disease, in whom sodium valproate is used.

(h) **Withdrawal** of a drug should be slow over a period of **at least 2 years** after the drug has been used. If there is relapse, the drug should be given for 2-3 years.

Table 8.12

Conventional antiepileptic agents: mechanism of action, uses and adverse effects

Drug	Mechanism of action	Clinical use	Adverse effects
Phenobarbitone and Primidone	Primidone is biotransformed into phenobarbitone. Reduce seizure discharge. Action unclear but inhibits sodium and calcium conductance, inhibits glutamate effect on AMPA receptors and enhance GABA effect on chloride channels	All types except absence seizures (may worsen)	See under barbiturates
Phenytoin	Inhibits spread of seizure discharge. Action unclear but known to affect sodium, calcium and potassium conductance, facilitate GABA activity and stabilize neuronal membranes. Blocks high-frequency repetitive firing of action potentials (post-tetanic potentiation) by blocking sodium channels.	All types except absence seizures	Gum hyperplasia, nystagmus, vertigo, folate deficiency, osteomalacia, hirsutism, coarsening of facial features, neurotoxic skin rashes.
Carbamazepine	Similar to phenytoin	Like phenytoin. Trigeminal neuralgia, mania	Ataxia, diplopia, drowsiness, folate deficiency, hepatotoxicity, hepatic and renal dysfunction, idiosyncratic blood dyscrasias
Sodium valproate	Increases GABA by increased synthesis (stimulates glutamic acid decarboxylase) and reduced metabolism (inhibits GABA-T). May increase potassium conductance	Absence seizures. Grand mal, mixed grand mal-petit mal seizures	Commonly gastrointestinal complaints, alopecia, weight gain, acute pancreatitis, congenital defects
Ethosuximide	Unclear. Reduces calcium conductance, inhibits Na ⁺ /K ⁺ ATPase and GABA-T	Absence seizures	Gastric distress, euphoria, hallucinations, anxiety, hypersensitivity reactions, rashes, lupus, pancytopenia
Trimethadione	Active metabolite, dimethadione, acts like ethosuximide	Limited use in absence seizures	Sedation, glare effect, idiosyncratic dermatitis, pancytopenia, nephrotic syndrome
Clonazepam and clobazam	See under benzodiazepines	All types	See under benzodiazepines

during pregnancy because of virtual absence of teratogenicity.

If seizures are not controlled, phenobarbitone (100-200 mg i.v.), general anaesthesia, preferably with ether (neuromuscular block), may be required, paraldehyde may be chosen where resuscitative facilities are not available, because it induces minimal respiratory depression and hypotension.

II. DRUGS USED IN PARKINSONISM OTHER MOVEMENT DISORDERS

A. DRUGS USED IN PARKINSONISM

Parkinson's disease is a progressive disorder of movement due to degeneration of nigro-striatal dopaminergic neurons.

Lecture Note

Subject: HAP, 404T, SEM-4th

UNIT-V

**Submitted By: Arun Panda Sir
Hi-Tech College of Pharmacy**

- Hexafluorenum prolongs the action of succinylcholine.
- Ca^{++} channel blockers prolong the action of both types of neuromuscular blockers.

Antagonism

AntichE agents like neostigmine edrophonium are used to reverse the action of nondepolarizing blockers (See "Some therapeutic problems"). In the presence of prolonged acidosis it is difficult to reverse the action of nondepolarizing agents by antichE agents.

MORPHINE, OTHER OPIOID ANALGESICS AND OPIOID ANTAGONISTS

Morphine is a high efficacy opioid analgesic used most commonly for analgesic and nonanalgesic purposes and it is obtained from opium.

Opium is dried juice obtained from the unripe seed capsule of *Papaver somniferum*.

Chemically opium contains two types of alkaloids :

1. Phenanthrenes

Morphine 10-15%

Codeine 0.5%

Thebaine 0.2% (weak analgesic, potent convulsant not used clinically)

2. Benzylisoquinolines

Papaverine 1% - Generalized smooth muscle relaxant, noncompetitive antagonist of histamine, ACh and 5HT with restricted therapeutic uses.

Noscapine 6% used as antitussive.

Heterogeneity of opioid receptors :

Atleast there are three opioid receptors in the central nervous system. Those are mu (μ), kappa (κ) and delta (δ) receptors. Each category has got two subtypes.

Mu (μ) receptor stimulation causes analgesia, respiratory depression, miosis, reduced gastrointestinal motility and euphoria.

Kappa (κ) receptor stimulation by agonist produces analgesia, dysphoria and psychomimetic effects.

Agonists and antagonists of opioid receptors :

- Morphine and Fentanyl are agonists of all types of opioid receptors.
- Pentazocine, Butorphanol and Nalbuphine are antagonists of mu (μ) receptor and agonists of kappa (κ) receptor respectively.
- Naloxone and Naltrexone are antagonists of all opioid receptors.
- Nalorphine is antagonist of mu (μ) receptor and agonist of kappa (κ) receptor (less than pentazocine).

Endogenous opioid peptides :

Endorphins - Synthesized from large precursor molecule.

Enkephalins - Derived from proenkephalin A in adrenal cortex.

Dynorphins - Derived from proenkephalin B.

These peptides are chemically unrelated to morphine but they bind to and act via same opioid receptor.

Classes of narcotic analgesics :

Natural
Morphine
Codeine

Synthetic
Meperidine (Pethidine)
Alfentanil
Methadone

Opioid with mixed action (Agonist - Antagonist/partial agonist)
Pentazocine, Cyclazocine, Nalorphine, Nalbuphine, Buprenorphine, Butorphanol, Metazolinol, Dizocine.

Semisynthetic derivatives
Metopon, Oxymorphone, Hydromorphone
Hydrocodeine, Dihydrocodeine
Buprenorphine (Thebaine derivative also partial μ agonist)

Derivatives
Fentanyl, Sufentanil

Summary of pharmacological actions of Morphine :

Central actions : On central nervous system morphine has got depressant and stimulant actions.

- * Depressant actions lead to analgesia, sleep, depression of respiration, vasomotor centre, temperature regulating centre and cough centre.
- * Mood changes leading to euphoria or dysphoria
- * Drug dependence
- * Increased release of ADH and decreased release of ACTH, FSH and LH.

Stimulant actions lead to vomiting due to CTZ stimulation, miosis due to stimulation of Edinger Westphal nucleus.

Peripheral action : Vasodilation, reduction in peripheral resistance and hypotension
Histamine release
Bronchoconstriction
Increased smooth muscle tone and constipation
(See - "Some therapeutic problems")
Spasm of biliary tract

Mechanism of analgesic action :

Morphine is a potent narcotic analgesic. It relieves dull, continuous poorly localised pain better than sharp intermittent pain, which is relieved only in higher doses.

Morphine acts at supraspinal regions in midbrain, limbic system and cortex through μ receptors (specially μ_1) and at spinal region through kappa (κ) receptors and produces analgesic effect by following ways :

1. Reduces the emotional reactions (i.e. apprehension, fear, autonomic effects) to pain.
2. Elevates pain threshold and thereby reduces the perception of pain.
3. Induces sleep, which itself may raise the pain threshold.
4. Causes euphoria, which may contribute to its analgesic effect.
5. The patient's ability to tolerate pain is markedly increased, because pain no longer produces anxiety and fear.

6. In the spinal region, morphine acts on the substantia gelatinosa of the spinal cord and inhibits the release of excitatory transmitter from primary afferents carrying pain impulses and thus prevents entry of peripheral pain signals to CNS.

Therapeutic uses :

1. Severe painful condition associated with shock like burn
2. Myocardial infarction*
3. Pain of terminal illness (Cancer)
The usual starting dose is 5-10 mg 4 hrly by oral route. Patients develop gradual tolerance. Some patients require a doubling of their dose as often as every 1-2 weeks.
4. Circulatory shock, accidents etc. to relieve anxiety.
5. Pulmonary oedema to relieve dyspnoea - Morphine causes reduction of preload and afterload, relieves anxiety and decreases sensitivity of respiratory centres to stimuli from congested lungs (**non analgesic use**).
6. Preanaesthetic medication, postoperative pain.
7. Tetanus - To combat sympathetic overactivity morphine is a suitable alternative of combined beta and alpha adrenergic blocking agent.

Contraindications :

1. Head injury
 - Increased respiratory depression
 - Increased intracranial pressure
 - Cerebral and spinal ischemic effects may aggravate
 - Judgement of clinical improvement becomes obscure because of miotic and vomiting effects of morphine
2. Bronchial asthma (*See - "Some therapeutic problems"*)
3. Extremes of age :
Old age
 - Central nervous system depressant action of morphine is prominent in old age due to increased sensitivity.Neonates
 - Incomplete BBB
 - Reduced metabolic process
4. Undiagnosed abdominal pain : Morphine may complicate clinical assessment.

Preparations and dosage :

1. Morphine sulfate inj
 - S.C./I.M. - 10-20 mg for adult
 - I.V. - 2.5-10 mg for adult

Morphine salts are also used by oral, buccal, sublingual and rectal routes. Sustained formulations for oral and I.V. administration are also available.

2. Morphine sulfate tablets 10-30 mg for an adult
0.1-0.15 mg/kg of body wt for a child.

- Codeine is available as codeine sulfate and codeine phosphate. For greater analgesic activity it is given with aspirin or acetaminophen (Paracetamol). Usual analgesic dose is 30-60 mg 4-6 hrly whereas cough suppressant dose is 15-30 mg/oral 4-6 hrly. For analgesic purpose, high oral parenteral potency ratio (2 : 3) in comparison with that of morphine (1 : 6) and respect it has definite advantages over morphine. Its antitussive action probably involves receptors that bind codeine itself.
- Meperidine (Pethidine)** : It is a synthetic opioid and binds to opioid receptors, particularly receptors. In general 75-100 mg of pethidine hydrochloride inj parenterally is approximately equivalent to 10 mg of morphine sulfate. It is available as pethidine hydrochloride inj., given S/C and I.V. Usual dose 75-100 mg I.V.

Meperidine differs from morphine in certain respects which are as follows : -

- Unlike morphine, in therapeutic doses meperidine does not delay the birth process.
- Has less respiratory depressant action in the neonates.
- Has less spasmogenic effects and better oral efficacy.
- Usually does not suppress cough.
- Has got little hypnotic action.
- Does not constipate.
- Has shorter duration of analgesic action.

Meperidine congeners are

1. Diphenoxylate, Loperamide - These two as non analgesic doses slow gastrointestinal motility with definite constipating action, used in the treatment of diarrhoea (non specific antidiarrhoeal agents).
 2. Fentanyl - 100 times more potent than morphine
Sufentanil - 1000 times more potent than morphine with bradycardiac action
Alfentanil - has got positive inotropic action.
- These are particularly used during and after surgery for anaesthesia and to relieve post operative pain respectively.

Pentazocine : It appears to be either a weaker antagonist or a partial agonist at mu receptors and a powerful agonist at kappa receptors. Its pharmacological action on CNS is generally similar to that of morphine with the follow differences :

- In contrast to morphine (hypotension, bradycardia) in high dose it raises B.P. and causes tachycardia.
 - In patients with coronary arterial diseases I.V. pentazocine increases cardiac work because of elevation of mean aortic pressure, left ventricular end-diastolic pressure and mean pulmonary artery pressure (due to increased plasma catecholamine conc.), so pentazocine is better tolerated in cardiovascular diseases.
 - In opioid dependence pentazocine induces withdrawal syndrome. Psychomimetic effects are more than morphine.
 - Dependence liability, respiratory depression, sedation and constipation are less than morphine.
- Pentazocine can be administered both orally and parenterally (oral dose 25-100 mg 3-4 hrly I.M. inj 30-60 mg 3-4 hrly). A tablet preparation containing 50 mg pentazocine and 0.5 mg naloxone is available. This oral tablet with

In that case naloxone will produce aversive response. But this aversive response of naloxone will not occur when it is used orally because in that case naloxone will be detoxified by liver during first pass effect.


☞ **Nefopam** : It is an example of non opioid and non NSAID analgesic, useful for treatment of moderate pain in opioid addict. It does not cause constipation and respiratory depression. It is more potent analgesic than NSAID.

☞ **Drug abuse** : Drug abuse means the use of psychotropic substances (stimulants and depressants) in excessive way that would constitute a public health and social problems.

Classes of drugs causing abuse :

1. Opioids (Morphine, Heroin and Meperidine)
2. Cannabis (THC)
3. Depressants (Alcohol and Barbiturates)
4. Psychodelics (LSD)
5. Arylcyclohexylamines
6. Nicotine
7. Stimulants (Amphetamine, Cocaine)
8. Caffeine
9. Solvents (Paint - thinner)

In connection with drug abuse following terms are important :



☞ Physical dependence means physical illness if the drug is withdrawn.

☞ Psychological dependence means the emotional distress when the drug is withdrawn. It appears first.

☞ Both psychological and physical dependence can co-exist.

☞ Psychological dependence may not be associated with physical dependence.

☞ **Addiction** : It is "behavioral pattern of drug abuse characterised by overwhelming involvement with the use of a drug, the securing of its supply and a high tendency to relapse after withdrawal". Addict may not be physically dependent. Under some special circumstances patients can be physically dependent on narcotics but not addicted.

Drugs	Physical	Psychological	Withdrawal syndrome
Narcotics	++++	+++	++++
Alcohol	++++	+++	+
Phenobarbital	++++	+++	+
Amphetamine	+	+++	-
Cocaine	+	++	+
LSD	-	++	+
Nicotine	++	+	
Caffeine	+		

+, ++, +++, +++++ = Increasingly more powerful

- = No evidence

☞ Opiate abstinence syndrome :

Onset of syndrome 5-15 hrs after the last dose

Peak of syndrome 36-72 hrs after discontinuation

Offset of syndrome 5-8 days

Syndrome manifestations include nausea, diarrhoea, lacrimation, rhinorrhoea, profuse sweating, piloerection, muscle twitching; increased body temperature, respiratory rate and B.P.; insomnia, yawning with intense drug craving.

Treatment of the withdrawal syndrome (Detoxication):

- Readministration of sufficient opioid like methadone on first day, (See "Some therapeutic problems")
1 mg methadone equates with 3 mg morphine, 1 mg heroin and 20 mg meperidine. The drug is well tolerated and is used in dosage of 10-25 mg once or twice daily. Methadone is gradually withdrawn usually over 5-10 days (10 to 20% of dose is cut on each day).
- Non opiate approach for detoxication is done by central α_2 agonists like clonidine 100-300 μ g 2-4 times daily. As clonidine decreases the outflow of NAD, some signs of overactivity might be expected to be reduced. It is not well tolerated. Sedation and orthostatic hypotension are disadvantages. However, non addicting property is its definite advantage.
- Rehabilitation :
 - Methadone maintenance
 - Education and counseling which are important for improvement. Naltrexone, a long acting opiate antagonist is sometimes used for rehabilitation. Before administration of naltrexone, patient should be free of opiates for a minimum of 5 days.
- Neonatal addiction due to mother's drug abuse during pregnancy may be treated by administration of paregoric (Camphorated opium tincture) in a dose of 0.2 mg every 3-4 hrs initially followed by a dose in decreasing manner. Treatment lasts for a period of 10-20 days.

☞ Alcohols :

Alcohol (Ethyl alcohol/Ethanol) : It has both hydrophilic and lipophilic properties. Alcohol readily passes through blood-placenta barrier into the fetal circulation. The metabolism is relatively

independent of its conc. (Zero-order kinetics). Chronic ethanol consumption may induce microsomal mixed-function oxidases. Therefore, the metabolism of a variety of drugs may be impaired in chronic alcoholics.

Alcohol is primarily a CNS depressant and potentiates the effects of other CNS depressant drugs. In low conc. there is increase in gastric acid secretion. Higher conc. of alcohol produces certain ill effects on the absorption site and absorption of aminoacids, vitamins, minerals etc. Diuresis is also caused which is possibly due to inhibition of release of ADH. There may be alteration of sexual function because of reduced blood testosterone level.

Regarding its medical uses, the following are important :

1. When applied topically, antiseptic property is obtained (70% alcohol having maximum effect). In addition it cools skin and is useful to lower down high temperature.
2. In low-conc. alcohol beverages may improve appetite and sometimes useful in patients suffering from anorexia.
3. To provide relief of pain in certain neuralgias (trigeminal neuralgia) and inoperable carcinoma, absolute alcohol is injected to ganglia or nerves.
4. In methyl alcohol (Methanol) poisoning, larger amounts of ethyl alcohol is administered by I.V. It is also useful as I.V. infusion in the management of ethylene glycol poisoning.
5. I.V. alcohol is occasionally used to suppress uterine contractions and delay premature labour.
6. In acute pulmonary oedema resulting from left heart failure, ethanol mist has been used by inhalation to clear out the foam that may obstruct the respiratory airways.
7. As a night sedative in chronic alcoholics.

- **Treatment of alcohol withdrawal syndrome :**

- Thorough physical examination along with adequate rest and nutrition.
- The specific drug for alcohol is a long acting sedative-hypnotic. Benzodiazepines suit for the purpose. Chlordiazepoxide 10-15 mg or diazepam 10 mg is given every 4-6 hrs by I.V. on first day and then the dosage of either of the above drugs should be reduced gradually.
- B complex vitamins including thiamine.
- Rehabilitation

Motivation towards abstinence, maintenance of problem free life. As an adjunct, disulfiram is to be given as 250 mg daily at bed time. In the presence of ethyl alcohol disulfiram causes tremor, hypotension or hypertension, nausea and severe vomiting. Chronic alcoholics should be informed about the effects of the above drug. Disulfiram is contraindicated in diabetes mellitus, portal hypertension and heart diseases.

PSYCHOTROPIC DRUGS

- A. Antipsychotic drugs
- B. Antidepressant drugs
- C. Mood stabilising drugs (Antimanic)
- D. Antianxiety drugs
- E. Hallucinogens

A. Antipsychotics or Neuroleptics

- Chlorpromazine Chlorprothixene
- Fluphenazine Loxapine
- Perphenazine Newer agents e.g.
- Haloperidol Clozapine, Sulpiride

These are all dopamine antagonist.

Therapeutic uses :

- Schizophrenia
- Acute manic episodes (in combination with lithium)
- Psychotic and agitated depression (in combination with antidepressants)

Adverse effects :

1. Sedation, lethargy and drowsiness — tolerance develops; drymouth, postural hypotension, cycloplegia, constipation, urinary retention.
2. Troublesome side effects —
 - Acute muscular dystonic reaction
 - Extrapyramidal parkinson like syndrome (treated by Benztropine mesylate)
 - Akathisia (reduction of dose and treated by beta blockers)
3. Most serious side effects :
 - Tardive dyskinesia (20–40%)

B. Antidepressants :

There are three different groups of drugs used for the treatment of affective disorders :

1. Tricyclic antidepressants (TCAs) — most commonly used.
2. Monoamine oxidase inhibitors (MAOs) — Drug-drug and drug-food interactions have made these the second-line medication in the treatment of depressive disorders.
3. Selective serotonin re-uptake inhibitors (SSRIs) — useful for refractory and atypical cases of depression.

No antidepressant is ideal. They have got the following characteristics :

- (a) Delayed onset of action (1–4 weeks),
- (b) Significantly sedative, anticholinergic, cardiotoxic and weight gain producing and
- (c) Induction of manic episode (mood-reversal) in patients with bipolar disorders.

Commonly used first generation antidepressants :

Drug	Action	Clinical features
Tricyclic derivatives		
Amitryptiline	Powerful blockade of 5HT uptake less blockade of NE uptake.	Prominent sedative and anticholinergic actions
Nortryptiline	Powerful blockade of NE uptake and less blockade of 5HT uptake.	Both sedative and anticholinergic actions are less than those of amitryptiline.
Imipramine	Equally powerful blockade of NE and and 5HT uptake.	Prominent anticholinergic action. No sedation may cause im-

Drug	Action	Clinical features
Desipramine	Very powerful inhibitor of NE uptake little or no blockade of 5HT uptake. Anxiolytic	Minimal sedative and anticholinergic action.
Doxepine Dothiepin	Potent NE and 5HT blockade.	Minimal adverse effect on CVS. Marked sedation. Less side effect, hence better patient compliance.
MAOIs Phenelgine	Most commonly used MAO inhibitor in Depression.	Drowsiness.
Tranlycypromine	Side chain cyclisation of amphetamine resulted in tranlycypromine. CNS stimulation.	Insomnia and tremors.
Isocarboxazid		Drowsiness.
Clorgyline Selegiline	Specific MAO-B inhibitor Has influence on DA system as well.	Same as other MAOIs. Very useful in the treatment of Parkinsonism.

Commonly used second generation antidepressants

Drug	Action	Clinical features
Tricyclic derivatives		
Trimipramine	Powerful inhibitor of 5HT uptake. Some inhibitory action on NE and DA uptake.	Prominent sedative action and moderate atropine-like action.
Amineptine	Potent NE and 5HT uptake inhibition and also DA blockade.	Less sedation. Less anticholinergic side effects. Useful in psychotic or endogenous depression.
Heterocyclics		
Amoxapine	Early onset of action within the first week is claimed.	Tardive dyskinesia, Parkinsonism.
Maprotiline		Fewer anticholinergic side effects. Lower dose is recommended. Blood dyscrasia.
Trazodone	High level of sedation and is useful as a hypnotic.	Increased risk of priapism.
Selective serotonin reuptake inhibitors (SSRIs)		
Fluoxetine	Relatively selective 5HT reuptake inhibition. Early onset of action.	Nausea, diarrhoea, tremor weightloss, agitation, Anorgasmia.
Sertraline	Same as above	Lesser side effect profile. Less chance of overdosage and suicide.

Mechanism of action of TCAs :

1. Increased synaptic conc. of monoamines neurotransmitters in the CNS by blocking the synaptic uptake of NE, 5HT and dopamine.
2. Regulation of postsynaptic receptor activity of monoaminergic neurones.
3. Down-regulation of neurotransmitter receptors.

Common side effects of TCAs :

Anticholinergic
Dry mouth Nausea,
vomiting constipation,
urinary retention, blurred
vision.

Cardiovascular
Postural hypotension
tachycardia, arrhythmia

Miscellaneous
Drowsiness, sleepiness, fine
tremor, dizziness, ataxia,
leucopenia.

Most common side effects are dry mouth, sedation, fine tremor of the hands and postural hypotension.

Mechanism of action of MAOIs :

Increased availability of one or more monoamines in the monoaminergic neurones of the CNS is unexplained delay of antidepressant effects for 2-3 weeks although maximal inhibition of monoamine metabolism is achieved within few days MAOIs are used when TCAs show unsatisfactory result or are not tolerated or accepted by the patient. They are also of considerable benefit in atypical depression (depression associated with hyperphagia, hypersomnia etc.) in panic attacks, agoraphobia, social phobia, psychalgia etc.

Common side effects of MAOIs :

Agitation, hallucinations, hyper-reflexia, insomnia and convulsion.

Drug interaction with MAOIs :

Indirectly acting sympathomimetics and cocaine cause hypertensive reactions.
(see "Cheese reaction")

Q. 1. What to do if an antidepressant fails to bring clinical improvement?

Ans. Actually there are several methodological steps :

- a) See whether the drug has been used in adequate dose for adequate time or not. It is better to use over-dose than under-dose in the treatment of depression.
- b) See whether the patient has been taking the drug as per instruction or not — because usually the patient compliance is poor due to undue sedation and other hyperadrenergic or anticholinergic side effects.
- c) If everything cited above goes right, the group of the drug may be changed, e.g. TCA to MAOI or SSRI or vice-versa .
- d) If still no improvement, go for 'potentiation'— i.e. clinical effects on addition of some other drugs like antipsychotics, lithium and thyroxine.
- e) If no improvement, 'Re-evaluation of diagnosis' and other modes of therapy may be needed. Some cases of depression may be secondary to pancreatic neoplasm, endocrinopathy or other disease of SOL in the CNS, in which eradication of the primary cause is mandatory to bring out clinical result.

C. Mood stabilising drugs :

- a) Lithium carbonate — A drug of low therapeutic index.
- b) Carbamazepine
- c) Sodium valproate
- d) Propranolol.

Drugs (b) and (c) are used when lithium fails to bring optimum clinical benefit, i.e. in cases of lithium non-responders and also in rapid cycling mood disorders.

Lithium carbonate

Mechanism of action :

1. Lithium partly replaces sodium specially in hyperexcitable tissues (of CNS, kidney and heart) and it has a relatively small gradient of distribution across the cell membranes. Although lithium can replace Na^+ to support a single action potential in a nerve cell, it is not an adequate substrate for the Na^+ pump and so cannot maintain membrane potential. Lithium thus inhibits the release of NAD, dopamine but not serotonin at the synapse.
2. In mania, hyperactive neurones require excess amount of inositol for its activity. Lithium inhibits the hydrolysis of inositol monophosphate to free inositol. Supply of free inositol from extracellular sources is very poor, so the hyperactive neurones suffer from deficiency of free inositol and excitability is reduced.

Pharmacokinetics

Route of administration	Oral
Bioavailability	100%
Half-life	18-20 hrs. (longer in elderly)
Therapeutic plasma conc.	0.8-1.2 mmol/L in mania. 0.4-0.8 mmol/L (Prophylactic)
Response starts after	2-4 weeks.

Therapeutic uses :

1. Acute manic/hypomanic episodes.
2. Prophylactic for recurrent episodes of mania and depression in bipolar illness.
3. Prophylaxis for recurrent unipolar depressive disorders.
4. In certain cases of pre-menstrual tension syndrome.
5. SIADH.
6. In certain childhood behaviour disorders, e.g. autism.
7. Hypoplastic anemia (because of its stimulatory effects on the bone marrow — one nonpsychiatric condition.)

Drug interactions :

1. Diuretics increase serum lithium conc. due to more reabsorption of lithium from the convoluted tubules.
2. Indomethacin increases serum lithium conc.
3. Haloperidol causes encephalopathic syndrome.

Treatment of lithium poisoning :

1. Mannitol I.V. to accelerate renal excretion (Amiloride also increases lithium excretion).
2. Dialysis in severe poisoning.

☞ Drugs causing anxiety

- Caffeine - intoxication
- Sedative - hypnotic withdrawal
- Amphetamine
- Glucocorticoids

Drugs causing depression

- Reserpine
- Glucocorticoids
- Oral contraceptives
- Amphetamine
- Indomethacin

☞ Drugs for some neurological disorders :

Conditions	Amitriptyline Drugs
Muscle spasticity	Baclofen, Dantrolene, Diazepam
Essential tremor	Propranolol
Hypokalemic paralysis	Propranolol
Hyperkalemic paralysis	Salbutamol inhalation
Pain following nerve injury	Tricyclic antidepressants
	Doxepin
	Imipramine
	Nortriptyline
	Desimipramine (Desipramine)
Tinnitus	Lignocaine
Trigeminal neuralgia	Anticonvulsants
	Phenytoin, Carbamazepine,
	Clonazepam

N.B. - Antihistamine (H_1 receptor blocker) hydroxyzine potentiates the action of narcotic analgesic increasing the sedative action.
- Dextroamphetamine enhances analgesia and makes and patients more sedated by narcotics.